Rain Therapeutics Inc., a California company developing targeted cancer therapies with a biomarker-based strategy, has raised a $63 million series B round led by Boxer Capital to support its development of the small-molecule MDM2 inhibitor RAIN-32 (milademetan) for the potential treatment for liposarcoma and other cancers.